Moderna, Inc. vs NRG Energy Inc — how do they compare? Moderna, Inc. trades at $137.23 (market cap $56.02B), while NRG Energy Inc trades at $116.71 (market cap $25.15B). The key difference: Moderna, Inc. is far larger — about 2.2× NRG Energy Inc's market cap, and NRG Energy Inc pays a 1.59% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| MRNA | NRG | |
|---|---|---|
Market Cap | $56.02B | $25.15B |
Sector | Health | Utilities |
52-Week High | $174.38 | $184.03 |
52-Week Low | $22.36 | $109.51 |
Enterprise Value | $52.17B | $49.10B |
Dividend Yield | — | 1.59% |
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $140.33, down 3.59% on the day, amid mixed signals. The stock has seen volatility, with a 143% surge over the past month driven by positive cancer vaccine trial results (Fox Business, 2026-09-06), but faces headwinds from declining revenue and persistent net losses. Technical analysis shows a bullish overall signal, with support at $138 and resistance at $145, while fundamentals reveal a challenging profit margin of -142.58% for 2026.
The outlook hinges on pipeline successes, particularly in oncology, but high valuation ratios and competitive pressures pose risks. Analyst consensus is cautious, with a $90.08 price target, reflecting skepticism despite recent clinical milestones. Investors should weigh innovation potential against financial sustainability and market sentiment shifts.
NRG Energy trades at $119.64, up 0.52% on the day, with a bullish technical signal and key support at $118. Recent Q2 2026 earnings missed estimates, but revenue grew 11% year-over-year. The company is pursuing growth via a 1.2 GW Texas data center power project and reaffirmed 2026 guidance, while analyst consensus remains strongly positive with a $201.29 price target.
The outlook is supported by strategic investments in data center demand and shareholder returns, but risks include rising interest costs, high leverage, and execution challenges. The stock offers significant upside to analyst targets if growth initiatives deliver, though near-term volatility may persist amid earnings misses and macroeconomic pressures.
Trailing returns across standard periods
Latest headlines on both assets
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →NRG Energy is one of the largest retail energy providers in the U.S., with 7 million customers, including its 2021 acquisition of Direct Energy. It also is one of the largest U.S. independent power producers, with 16 gigawatts of nuclear, coal, gas, and oil power generation capacity primarily in Texas. Since 2018, NRG has divested its 47% stake in NRG Yield, among other renewable energy and conventional generation investments. NRG exited Chapter 11 bankruptcy as a stand-alone entity in December 2003.
Read more on NRG →